soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Reduces CV Events in T2DM – (NEJM, Mar 2025) Relevant for: cardiology, diabetology, nephrology, internal medicine 🧪 T2DM + ASCVD/CKD 💊 Oral semaglutide 14 mg vs placebo 📉 Cardiovascular risk reduction with once-weekly

Explore BPC-157, TB-500, L-Carnitine, and morequality you can trust.

If you're experiencing hair thinning during GLP-1 treatment, bring it up with your doctor and consider having your ferritin and vitamin D levels tested

After propensity score matching, 171,105 patients were included in each group

Understand the causes of needle pain, injection site reactions, and practical strategies to make your GLP-1 therapy more comfortable at PlexusDx

The Thermo Fisher solution is entirely managed in the Chromeleon CDS ecosystem, simplifying method development and verification steps to increase productivity

NEML NOT: Bu bilgiler genel bilgilendirme amaldr